Over his eight years as CEO, Novo’s sales, profits and share price have almost tripled, the company said. However, the shares ...

Wegovy and Ozempic-maker Novo Nordisk said today its CEO Lars Fruergaard Jorgensen will step down over concerns the company is losing its first-mover advantage in the highly competitive obesity drug ...